Circio Holding (”Circio” or ”the Company”) announced, on the 18th of March 2026, that one of the Company’s submitted abstracts has been selected for an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) annual meeting, to be held in Boston, 11–15 May 2026. ASGCT represents the largest and most prestigious gene and cell therapy conference globally, where only a small fraction of submitted abstracts are selected for oral presentations, while also serving as a key venue where companies and potential partners convene to explore licensing and collaborative R&D opportunities.
Analyst Group’s View on the ASGCT Selection
Analyst Group views the selection for oral presentation at ASGCT 2026 as a meaningful validation of Circio’s circVec technology platform, and one that carries additional weight in the context of the Company’s recently reported preclinical data. In February 2026, Circio demonstrated up to 50x enhanced gene expression in the eye and reproduced approx. 40x enhanced expression in the heart using the Company’s AAV-circVec 4.0 construct, a data package that materially strengthened circVec’s credibility as a scalable, cross-tissue gene expression platform. The ASGCT selection suggests this body of work has resonated at the scientific committee level, which Analyst Group considers a credible third-party endorsement of its quality and relevance.
Analyst Group assesses that presenting circVec’s cross-tissue validation, including approx. 10x outperformance retained even at a 90% reduced dose level, could meaningfully advance Circio’s visibility among potential licensing partners at a time when circular RNA is attracting significant Big Pharma attention. This is underscored by Bristol Myers Squibb’s acquisition of Orbital Therapeutics for USD 1.5bn in Q4-25 and Eli Lilly’s acquisition of Orna Therapeutics for up to USD 2.4bn in Q1-26, reflecting the strategic premium large pharmaceutical companies are willing to assign to differentiated RNA expression technologies.
Analyst Group notes that the previously reported heart data contributed to securing Circio’s first fully funded feasibility study with a top-tier global pharmaceutical partner. With a broader and strengthened preclinical data package now in place, and with disease-model efficacy data in eye and heart as well as in vitro circVec data in primary human T-cells and T-cell targeted delivery in vivo expected in Q2-26, the ASGCT presentation provides a well-timed platform to engage both existing and prospective partners ahead of these upcoming value-inflection points. The content of the selected abstract remains undisclosed until 13 April 2026, at which point the full scientific scope of the presentation will become assessable.
In summary, Analyst Group views Circio’s selection for an oral presentation at ASGCT 2026 as a qualitatively positive milestone that, when viewed alongside the Company’s recently reported preclinical data, reinforces the growing credibility of the circVec platform. Analyst Group assesses that the combination of a strengthened data package, an upcoming high-profile scientific presentation, and a strong balance sheet positions Circio favorably for deepened partner dialogues and broader industry recognition in the months ahead.
About Circio
Circio Holding ASA is a biotechnology company developing a circular RNA expression platform for gene and cell therapy. The proprietary circVec technology is a DNA-based system enabling durable intracellular circular RNA production, addressing the limited stability of conventional mRNA. The platform supports viral and non-viral delivery and has demonstrated up to 50-fold higher protein expression in preclinical studies. R&D is conducted through the wholly owned subsidiary Circio AB. Circio also retains a non-core legacy immunooncology asset, TG01, evaluated in externally sponsored clinical studies. The Company has been listed on Oslo Børs since 2016.
